A doctor by training who now runs research, development and medical affairs at one of neuroscience's most watched biopharma companies - and keeps the patient at the center of every decision.
A doctor makes a decision about one person at a time. You sit across from someone, read the chart, weigh the options, and you find out fairly quickly whether you were right. Craig Hopkinson trained for exactly that work, earning his medical degree in South Africa. Then he walked away from the clinic to do something with a much longer feedback loop and a much wider reach - build the medicines themselves.
Today he is Executive Vice President of Research & Development and Chief Medical Officer at Alkermes, a biopharmaceutical company focused on neuroscience. The title undersells the job. Most companies split their science across separate leaders. Hopkinson holds an unusually wide remit: discovery, pharmaceutical development, early and late clinical development, regulatory affairs, clinical operations, the project management office, and medical affairs all report up through him. In practice, that means he owns the entire chain from a molecule on a bench to a medicine a patient can actually use.
The jump from physician to drug developer is bigger than the resumes make it look. In a clinic, results arrive in days. In development, a decision you make today might not prove itself for a decade. You have to hold conviction across years of uncertainty, funding cycles and data readouts that could go either way. It is a different muscle, and Hopkinson has spent nearly three decades training it.
His path runs through some of the industry's best-known names. Before Alkermes he was Senior Vice President of Medicines Development and Head of Global Medical Affairs at Vertex Pharmaceuticals. Earlier he held a run of executive roles at Eisai Pharmaceuticals - including President of the Frontier Product Creation Unit and Vice President of Medical Affairs for oncology - and leadership positions at Elan, Actelion and Pfizer. He joined Alkermes in 2017 as Chief Medical Officer, and his mandate has only grown since.
One thing stands out on close reading of Hopkinson's career: he did not specialize forever. He has led development teams across neuroscience, oncology, gastroenterology, infectious disease, cardiovascular conditions, inflammation, genetic disease, hematology and neurodegenerative disease. That is not restlessness. Each therapeutic area teaches a different way a drug can fail - a different regulatory path, a different trial design, a different failure mode. Collect enough of them and you start to recognize trouble before it arrives.
So when he took over the full research organization at Alkermes, he was not learning the job from scratch. He was applying a pattern he had already watched play out from many angles. That breadth is part of why the whole chain - discovery through regulatory - sits under one leader here rather than being handed off between silos. Good ideas tend to die in the seams between teams. Owning the seams is the point.
Alkermes has built its identity around the brain, and the company's most closely watched science lives in that space. Hopkinson has been public about the appeal of the underlying biology - the idea that if you understand the mechanism of a condition well enough, you can design an agent that addresses the root of it rather than just the symptoms. That conviction is the through-line of the pipeline his org is advancing.
It is a scientist's framing, and that is the point. Hopkinson reads clinical data the way a physician reads a chart - with the patient at the far end of every number. Colleagues and press releases return to the same theme again and again: the research exists to understand the real experience of the people who take these medicines, not just to clear a statistical bar. In an industry that can drift toward abstraction, keeping that anchor is itself a discipline.
There is a quiet lesson buried in a career like this. Most jobs reward fast feedback - you do a thing, you see the result, you adjust. Drug development rewards the opposite. You commit resources and conviction to a program, then wait years to learn whether you were right, and much of the time you are not. The people who thrive are not necessarily the smartest in the room. They are the ones who can sit with uncertainty long enough to let the science answer.
Hopkinson also stepped outside the operating role for a stretch, serving on the board of Albireo Pharma from late 2022 until Ipsen acquired the company in early 2023. Board work is a different vantage point - less hands-on, more about pattern recognition and judgment across an entire company. It is the kind of experience that tends to sharpen an executive's sense of what actually moves a business versus what merely looks busy.
Strip away the titles and the org charts, and Hopkinson's career answers one question over and over: what does it actually take to get a molecule to a patient? He could have kept treating people one at a time and done real good. Instead he chose the lever that reaches people he will never meet - the slow, uncertain, deeply technical work of building medicines at scale. The title has grown from Chief Medical Officer to EVP of Research & Development. The question has not changed at all.
That is the useful thing to take from a story like this. Pick your question carefully, because you might be answering it for thirty years. Hopkinson picked his early - patient impact at scale - and let it pull him through five companies and a dozen disease areas. The org chart kept shifting. The direction never did.